Nutex Health vs Phreesia
NUTX and PHR side by side, both in miscellaneous business services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NUTX and PHR compare
Nutex Health is the larger company, worth 1.6 times as much as Phreesia ($1.3B against $795M).
On earnings, Nutex Health is cheaper: it trades at 8.1× trailing earnings, against 75.4× for Phreesia.
Phreesia grew revenue faster over the last twelve months (12.9% versus −18.8% for Nutex Health).
Nutex Health keeps more of each dollar of sales as profit, with a net margin of 20.7% compared with 2.1% at Phreesia.
Nutex Health scores higher on the StockData Score (15 against 8 for Phreesia), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NUTX | PHR |
|---|---|---|
| Size and price | ||
| Market cap | $1.3B | $795M |
| Share price | $189.19 | $12.81 |
| Change, 1 year | 59.2% | −43.4% |
| Change, 5 years | −69.6% | −81.1% |
| Beta (5Y) | 1.86 | 1.53 |
| Employees | 944 | 1,789 |
| StockData Score | ||
| Total score | 15 (better) | 8 |
| Valuation score | 4 (better) | 1 |
| Growth score | 2 | 3 (better) |
| Performance score | 4 (better) | 1 |
| Health score | 5 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 8.1× (better) | 75.4× |
| P/S | 1.6× | 1.6× (better) |
| P/B | 3.0× | 2.1× (better) |
| EV/EBITDA | 3.6× (better) | 15.8× |
| P/FCF | 5.2× (better) | 9.8× |
| FCF yield | 19.1% (better) | 10.2% |
| Fair value | $570.15 | $9.74 |
| Margin of safety | 66.8% (better) | −31.6% |
| Growth | ||
| Revenue growth (TTM) | −18.8% | 12.9% (better) |
| Revenue growth, 5Y average | 26.1% | 26.4% (better) |
| Net income growth (TTM) | 36.5% | – |
| EPS growth (TTM) | 21.2% | – |
| EPS growth, 5Y average | −17.2% | – |
| Profitability | ||
| Gross margin | 47.8% | 85.4% (better) |
| Operating margin | 39.0% (better) | 2.5% |
| Net margin | 20.7% (better) | 2.1% |
| FCF margin | 31.1% (better) | 15.9% |
| Return on equity | 43.8% (better) | 3.1% |
| Return on invested capital | 117% (better) | 4.4% |
| Financial health | ||
| Debt / equity | 0.10 (better) | 0.18 |
| Net debt / EBITDA | −0.62 | −0.16 |
| Interest coverage | 16.2× (better) | 1.2× |
| Current ratio | 4.76 (better) | 1.76 |
| Altman Z-score | 3.75 (better) | 1.07 |
| Piotroski F-score | 7 (better) | 6 |
| Dividends and buybacks | ||
| Buyback yield | 4.3% | – |
| Shareholder yield | 4.3% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 42.9% | 94.0% |
| Held by insiders | – | 22.7% |
| Insider net buying, 12 months | $2.2K | $26.8M (better) |
| Short interest, % of float | – | 6.3% |
Go deeper
- NUTX stock overview
- NUTX income statement
- NUTX valuation and score
- PHR stock overview
- PHR income statement
- PHR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.